General form of registration statement for all companies including face-amount certificate companies

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

v3.2.0.727
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Dec. 31, 2014
Dec. 31, 2013
Income Statement [Abstract]            
Product sales, net $ 2,413,886 $ 3,005,786 $ 5,127,938 $ 5,637,655 $ 10,190,667 $ 2,154,063
Cost of Goods Sold 1,055,026 1,209,970 2,138,108 2,230,973 4,387,002 880,470
Gross Profit 1,358,860 1,795,816 2,989,830 3,406,682 5,803,665 1,273,593
Operating Expenses:            
Selling, general and administrative 2,920,852 1,507,423 6,911,027 2,431,789 13,357,633 2,366,450
Research and development 433,544 156,501 744,022 307,522 999,280 524,476
Total Operating Expenses 3,354,396 1,663,924 7,655,049 2,739,311 14,356,913 2,890,926
Operating (Loss) Income (1,995,536) 131,892 (4,665,219) 667,371 (8,553,248) (1,617,333)
Other income (expense):            
Interest income 33,446 9,232 70,488 0 30,703 0
Interest expense (16,124) 0 (16,124) (606,112) (615,344) (372,109)
Allocated losses on KannaLife Sciences investment 0 0 0 (38,552) (38,552) (310,754)
Gain on sale of equity investment 0 7,899,306 0 7,899,306 7,899,306 0
Other         (34,816) 0
Total Other Income (Expense) 17,322 7,908,538 54,364 7,254,642 7,241,297 (682,863)
(Loss) income before taxes (1,978,214) 8,040,430 (4,610,855) 7,922,013 (1,311,951) (2,300,196)
Provision for income taxes 24,854 0 41,003 0 0 0
Net (Loss) Income $ (2,003,068) $ 8,040,430 $ (4,651,858) $ 7,922,013 $ (1,311,951) $ (2,300,196)
(Loss) income per share $ (.06) $ .24 $ (.13) $ .27 $ (0.04) $ (0.23)
Weighted average number of shares - basic & diluted 34,973,630 33,350,273 34,582,638 29,866,312 31,581,101 9,879,098